drugset
drugset / Trial / NCT06779253

A Study to Investigate The Effect of Pimicotinib on The Pharmacokinetics of Metformin, Fexofenadine and Rosuvastatin In Healthy Subjects

NCT06779253 ↗

Phase 1 Completed 39 enrolled Abbisko Therapeutics Co, Ltd
NaSingle-groupOpen-labelOther

Summary

This is a an open-label, fixed-sequence DDI study conducted in Chinese healthy subjects to investigate the effect of multiple oral doses of pimicotinib on the pharmacokinetics of fexofenadine , rosuvastatin and metformin . Fexofenadine and rosuvastatin will be administered together as a cocktail, and metformin will be given via staggered dosing from the cocktail drugs administration. Approximately 38 healthy subjects will be enrolled to achieve 28 evaluable healthy subjects complete the study. Blood samples will be collected for PK analysis .

Timeline

Start
2025-03-14
Primary completion
2025-04-04
Completion
2025-05-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Pimicotinib Small molecule 50 mg Oral

Indications

No indication recorded.